Identification

Name
Dolasetron
Accession Number
DB00757  (APRD00518)
Type
Small Molecule
Groups
Approved
Description

Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.

Structure
Thumb
Synonyms
  • Dolasetron
  • Dolasétron
  • Dolasetronum
External IDs
MDL 73147 EF
Product Ingredients
IngredientUNIICASInChI Key
Dolasetron MesylateU3C8E5BWKR878143-33-0QTFFGPOXNNGTGZ-UXSNJBPXSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnzemetInjection100 mg/5mLIntravenousSanofi Aventis1997-09-11Not applicableUs
AnzemetTablet50 mgOralSanofi Aventis1997-08-262010-01-01Canada
AnzemetTablet, film coated50 mg/1OralValidus Pharmaceuticals1997-09-11Not applicableUs
AnzemetTablet, film coated50 mg/1OralSanofi Aventis1997-09-11Not applicableUs
AnzemetTablet100 mgOralSanofi Aventis1997-08-262014-04-21Canada
AnzemetInjection12.5 mg/.625mLIntravenousSanofi Aventis1997-09-11Not applicableUs
AnzemetTablet, film coated100 mg/1OralValidus Pharmaceuticals1997-09-11Not applicableUs
AnzemetTablet, film coated100 mg/1OralSanofi Aventis1997-09-11Not applicableUs
AnzemetInjection500 mg/25mLIntravenousSanofi Aventis1997-09-11Not applicableUs
AnzemetTablet, film coated100 mg/1OralAvera Mc Kennan Hospital2016-07-26Not applicableUs
International/Other Brands
Anemet (Sanofi-Aventis) / Zamanon (Sanofi-Aventis)
Categories
UNII
82WI2L7Q6E
CAS number
115956-12-2
Weight
Average: 324.38
Monoisotopic: 324.147392512
Chemical Formula
C19H20N2O3
InChI Key
UKTAZPQNNNJVKR-KJGYPYNMSA-N
InChI
InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11-,12-,13+,14+
IUPAC Name
(1s,3R,5r,7S)-10-oxo-8-azatricyclo[5.3.1.0³,⁸]undecan-5-yl 1H-indole-3-carboxylate
SMILES
[H][[email protected]@]1(C[[email protected]@]2([H])C[[email protected]]3([H])C[[email protected]@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2

Pharmacology

Indication

For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.

Structured Indications
Pharmacodynamics

Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. It is structurally and pharmacologically related to other 5-HT3 receptor agonists. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. It is suggested that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.

Mechanism of action

Dolasetron is a selective serotonin 5-HT3 receptor antagonist. In vivo, the drug is rapidly converted into its major active metabolite, hydrodolasetron, which seems to be largely responsible for the drug's pharmacological activity. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.

TargetActionsOrganism
A5-hydroxytryptamine receptor 3A
antagonist
Human
Absorption

Orally-administered dolasetron is well absorbed

Volume of distribution
  • 5.8 L/kg [adults]
Protein binding

69-77%

Metabolism

Hepatic

Route of elimination

Hydrodolasetron is eliminated by multiple routes, including renal excretion and, after metabolism, mainly glucuronidation, and hydroxylation.

Half life

8.1 hours

Clearance
  • Apparent cl=9.4 mL/min/kg [Healthy volunteers with IV treatment dose up to 5 mg/kg]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Dolasetron can be increased when it is combined with Abiraterone.Approved
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
AlmotriptanDolasetron may increase the serotonergic activities of Almotriptan.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Dolasetron.Approved
AmiodaroneThe metabolism of Dolasetron can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Dolasetron.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Dolasetron.Approved
AnagrelideDolasetron may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineDolasetron may increase the hypotensive activities of Apomorphine.Approved, Investigational
AprepitantThe serum concentration of Dolasetron can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
Arsenic trioxideDolasetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Dolasetron can be decreased when combined with Artemether.Approved
AsenapineDolasetron may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Dolasetron can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Dolasetron.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Dolasetron.Approved
BedaquilineDolasetron may increase the QTc-prolonging activities of Bedaquiline.Approved
BetaxololThe metabolism of Dolasetron can be decreased when combined with Betaxolol.Approved
BoceprevirThe metabolism of Dolasetron can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
BosentanThe serum concentration of Dolasetron can be decreased when it is combined with Bosentan.Approved, Investigational
BromocriptineDolasetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
BupropionThe metabolism of Dolasetron can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Dolasetron.Approved
BuspironeDolasetron may increase the serotonergic activities of Buspirone.Approved, Investigational
CabergolineDolasetron may increase the serotonergic activities of Cabergoline.Approved
CapecitabineThe metabolism of Dolasetron can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Dolasetron can be increased when combined with Carbamazepine.Approved, Investigational
CelecoxibThe metabolism of Dolasetron can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Dolasetron can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
CholecalciferolThe metabolism of Dolasetron can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Dolasetron can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Dolasetron can be decreased when combined with Cinacalcet.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
CisaprideDolasetron may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramDolasetron may increase the serotonergic activities of Citalopram.Approved
ClarithromycinDolasetron may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Dolasetron can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Dolasetron can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
ClotrimazoleThe metabolism of Dolasetron can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Dolasetron.Approved
CobicistatThe serum concentration of Dolasetron can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Dolasetron can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Dolasetron can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Dolasetron can be decreased when combined with Crisaborole.Approved
CrizotinibDolasetron may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineDolasetron may increase the serotonergic activities of Cyclobenzaprine.Approved
CyclosporineThe metabolism of Dolasetron can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Dolasetron can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe metabolism of Dolasetron can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Dolasetron can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dolasetron can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Dolasetron can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Dolasetron.Approved
DelavirdineThe metabolism of Dolasetron can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Dolasetron.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Dolasetron.Approved
DesvenlafaxineDolasetron may increase the serotonergic activities of Desvenlafaxine.Approved
DextromethorphanDolasetron may increase the serotonergic activities of Dextromethorphan.Approved
DihydroergotamineThe metabolism of Dolasetron can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Dolasetron can be decreased when combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Dolasetron.Approved
DisopyramideDolasetron may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideDolasetron may increase the QTc-prolonging activities of Dofetilide.Approved
DomperidoneDolasetron may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Dolasetron can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Dolasetron.Approved
DoxycyclineThe metabolism of Dolasetron can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Dolasetron can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
DuloxetineDolasetron may increase the serotonergic activities of Duloxetine.Approved
EfavirenzThe metabolism of Dolasetron can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanDolasetron may increase the serotonergic activities of Eletriptan.Approved, Investigational
EliglustatThe metabolism of Dolasetron can be decreased when combined with Eliglustat.Approved
EnzalutamideThe serum concentration of Dolasetron can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateDolasetron may increase the serotonergic activities of Ergoloid mesylate.Approved
ErgonovineDolasetron may increase the serotonergic activities of Ergonovine.Approved
ErgotamineDolasetron may increase the serotonergic activities of Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
EscitalopramDolasetron may increase the serotonergic activities of Escitalopram.Approved, Investigational
EtravirineThe metabolism of Dolasetron can be decreased when combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Dolasetron.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Dolasetron.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Dolasetron.Approved
FentanylDolasetron may increase the serotonergic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dolasetron.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
FlecainideDolasetron may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloxuridineThe metabolism of Dolasetron can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Dolasetron can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Dolasetron can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Dolasetron can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolDolasetron may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvastatinThe metabolism of Dolasetron can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Dolasetron can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
FosamprenavirThe metabolism of Dolasetron can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dolasetron can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Dolasetron.Approved
FosphenytoinThe metabolism of Dolasetron can be increased when combined with Fosphenytoin.Approved
FrovatriptanDolasetron may increase the serotonergic activities of Frovatriptan.Approved, Investigational
Fusidic AcidThe serum concentration of Dolasetron can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Dolasetron.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Dolasetron.Approved
GemfibrozilThe metabolism of Dolasetron can be decreased when combined with Gemfibrozil.Approved
GemifloxacinDolasetron may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Dolasetron.Approved
GranisetronDolasetron may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Dolasetron.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Dolasetron.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Dolasetron.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
IbutilideDolasetron may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Dolasetron can be increased when it is combined with Idelalisib.Approved
IloperidoneDolasetron may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Dolasetron can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Dolasetron.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Dolasetron.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Dolasetron.Approved
IndinavirThe metabolism of Dolasetron can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Dolasetron can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Dolasetron can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidDolasetron may increase the serotonergic activities of Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
IsoniazidThe metabolism of Dolasetron can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Dolasetron.Approved
ItraconazoleThe metabolism of Dolasetron can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Dolasetron.Approved
IvacaftorThe serum concentration of Dolasetron can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Dolasetron can be decreased when combined with Ketoconazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
LeflunomideThe metabolism of Dolasetron can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibDolasetron may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
LevofloxacinDolasetron may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranDolasetron may increase the serotonergic activities of Levomilnacipran.Approved
LinezolidDolasetron may increase the serotonergic activities of Linezolid.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Dolasetron.Approved
LobeglitazoneThe metabolism of Dolasetron can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Dolasetron can be decreased when combined with Lopinavir.Approved
LorcaserinDolasetron may increase the serotonergic activities of Lorcaserin.Approved
LosartanThe metabolism of Dolasetron can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Dolasetron can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Dolasetron can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dolasetron can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Dolasetron can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Dolasetron can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Dolasetron.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Dolasetron.Approved
MequitazineDolasetron may increase the arrhythmogenic activities of Mequitazine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Dolasetron.Approved
MethotrimeprazineThe metabolism of Dolasetron can be decreased when combined with Methotrimeprazine.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dolasetron.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Dolasetron.Approved
MidostaurinThe metabolism of Dolasetron can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Dolasetron can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranDolasetron may increase the serotonergic activities of Milnacipran.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Dolasetron.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Dolasetron.Approved
MitotaneThe serum concentration of Dolasetron can be decreased when it is combined with Mitotane.Approved
MoclobemideDolasetron may increase the serotonergic activities of Moclobemide.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Dolasetron.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
NaratriptanDolasetron may increase the serotonergic activities of Naratriptan.Approved, Investigational
NefazodoneThe metabolism of Dolasetron can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dolasetron can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dolasetron can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dolasetron can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Dolasetron can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Dolasetron can be decreased when combined with Nilotinib.Approved, Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Dolasetron.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Dolasetron.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
OfloxacinDolasetron may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
OlaparibThe metabolism of Dolasetron can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Dolasetron.Approved
OmeprazoleThe metabolism of Dolasetron can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronDolasetron may increase the QTc-prolonging activities of Ondansetron.Approved
OsimertinibThe serum concentration of Dolasetron can be increased when it is combined with Osimertinib.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
PalbociclibThe serum concentration of Dolasetron can be increased when it is combined with Palbociclib.Approved
PaliperidoneDolasetron may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatDolasetron may increase the arrhythmogenic activities of Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Dolasetron can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Dolasetron.Approved
PazopanibDolasetron may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Dolasetron can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Dolasetron.Approved
PentobarbitalThe metabolism of Dolasetron can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Dolasetron.Approved
PethidineDolasetron may increase the serotonergic activities of Pethidine.Approved
PhenelzineDolasetron may increase the serotonergic activities of Phenelzine.Approved
PhenobarbitalThe metabolism of Dolasetron can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Dolasetron can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideDolasetron may increase the QTc-prolonging activities of Pimozide.Approved
PosaconazoleThe metabolism of Dolasetron can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimaquineDolasetron may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Dolasetron can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideDolasetron may increase the QTc-prolonging activities of Procainamide.Approved
ProcarbazineDolasetron may increase the serotonergic activities of Procarbazine.Approved
PromazinePromazine may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Dolasetron.Approved
PropafenoneDolasetron may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Dolasetron.Approved
PyrimethamineThe metabolism of Dolasetron can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineDolasetron may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineThe metabolism of Dolasetron can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Dolasetron can be decreased when combined with Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
RasagilineDolasetron may increase the serotonergic activities of Rasagiline.Approved
RifabutinThe metabolism of Dolasetron can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dolasetron can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dolasetron can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Dolasetron.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
RitonavirThe metabolism of Dolasetron can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanDolasetron may increase the serotonergic activities of Rizatriptan.Approved
RolapitantThe metabolism of Dolasetron can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Dolasetron can be decreased when combined with Ropinirole.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Dolasetron.Approved
SaquinavirDolasetron may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Dolasetron can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineDolasetron may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Dolasetron.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
SildenafilThe metabolism of Dolasetron can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dolasetron can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dolasetron can be increased when it is combined with Simeprevir.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Dolasetron.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
SotalolDolasetron may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Dolasetron can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Dolasetron can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Dolasetron can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Dolasetron.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
SumatriptanDolasetron may increase the serotonergic activities of Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Dolasetron.Approved
TapentadolDolasetron may decrease the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateDolasetron may increase the serotonergic activities of Tedizolid Phosphate.Approved
TelaprevirThe metabolism of Dolasetron can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinDolasetron may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinDolasetron may increase the QTc-prolonging activities of Telithromycin.Approved
TerbinafineThe metabolism of Dolasetron can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Dolasetron.Approved
TetrabenazineDolasetron may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dolasetron.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Dolasetron.Approved
TicagrelorThe metabolism of Dolasetron can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Dolasetron can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Dolasetron can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Dolasetron.Approved
TocilizumabThe serum concentration of Dolasetron can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Dolasetron can be decreased when combined with Tolbutamide.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
TopiroxostatThe metabolism of Dolasetron can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneDolasetron may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolDolasetron may decrease the analgesic activities of Tramadol.Approved, Investigational
TranylcypromineDolasetron may increase the serotonergic activities of Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Dolasetron.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Dolasetron.Approved, Vet Approved
Valproic AcidThe metabolism of Dolasetron can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Dolasetron can be decreased when combined with Valsartan.Approved, Investigational
VandetanibDolasetron may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Dolasetron.Approved
VemurafenibDolasetron may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Dolasetron.Approved
VerapamilThe metabolism of Dolasetron can be decreased when combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Dolasetron.Approved
VilazodoneDolasetron may increase the serotonergic activities of Vilazodone.Approved
VoriconazoleThe metabolism of Dolasetron can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
VortioxetineDolasetron may increase the serotonergic activities of Vortioxetine.Approved
ZafirlukastThe metabolism of Dolasetron can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Dolasetron can be decreased when combined with Ziprasidone.Approved
ZolmitriptanDolasetron may increase the serotonergic activities of Zolmitriptan.Approved, Investigational
ZuclopenthixolDolasetron may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Janos Hajko, Tivadar Tamas, Adrienne Kovacsne-Mezei, Erika Molnarne, Csaba Peto, Csaba Szabo, "Production of dolasetron." U.S. Patent US20070203219, issued August 30, 2007.

US20070203219
General References
  1. Balfour JA, Goa KL: Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997 Aug;54(2):273-98. [PubMed:9257083]
  2. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. [PubMed:9506240]
  3. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177]
External Links
KEGG Compound
C07866
PubChem Compound
3033818
PubChem Substance
46505209
ChemSpider
30845229
BindingDB
50451546
ChEMBL
CHEMBL2368925
Therapeutic Targets Database
DAP000368
PharmGKB
PA449390
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dolasetron
ATC Codes
A04AA04 — Dolasetron
FDA label
Download (93.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentProphylaxis against postoperative nausea and vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentFibromyalgia1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableTerminatedSupportive CareMalignant Digestive System Neoplasm / Nausea and Vomiting1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous100 mg/5mL
InjectionIntravenous12.5 mg/.625mL
InjectionIntravenous500 mg/25mL
TabletOral100 mg
TabletOral50 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
SolutionIntravenous20 mg
Prices
Unit descriptionCostUnit
Anzemet 100 mg tablet77.77USD tablet
Anzemet 50 mg tablet58.67USD tablet
Anzemet 100 mg Tablet32.16USD tablet
Anzemet 12.5 mg carpuject18.74USD syringe
Anzemet 20 mg/ml2.66USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4906755No1994-07-022011-07-02Us
CA1329203No1994-05-032011-05-03Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)278 °CNot Available
water solubilityFreely soluble in waterNot Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.261 mg/mLALOGPS
logP2.41ALOGPS
logP2.33ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)12.18ChemAxon
pKa (Strongest Basic)5.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.4 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity89.34 m3·mol-1ChemAxon
Polarizability35.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9956
Blood Brain Barrier+0.9403
Caco-2 permeable+0.5119
P-glycoprotein substrateNon-substrate0.5833
P-glycoprotein inhibitor IInhibitor0.5344
P-glycoprotein inhibitor IINon-inhibitor0.5225
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8569
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5387
CYP450 1A2 substrateInhibitor0.5293
CYP450 2C9 inhibitorNon-inhibitor0.6846
CYP450 2D6 inhibitorNon-inhibitor0.9093
CYP450 2C19 inhibitorNon-inhibitor0.7741
CYP450 3A4 inhibitorNon-inhibitor0.8272
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5698
Ames testNon AMES toxic0.6931
CarcinogenicityNon-carcinogens0.9407
BiodegradationNot ready biodegradable0.9963
Rat acute toxicity2.5853 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8902
hERG inhibition (predictor II)Non-inhibitor0.7459
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolecarboxylic acids and derivatives. These are compounds containing a carboxylic acid group (or a derivative thereof) linked to an indole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolecarboxylic acids and derivatives
Direct Parent
Indolecarboxylic acids and derivatives
Alternative Parents
Quinolizidines / Indoles / Quinuclidones / Pyrrole carboxylic acids and derivatives / Piperidinones / Benzenoids / Substituted pyrroles / Vinylogous amides / Heteroaromatic compounds / Ketones
show 8 more
Substituents
Indolecarboxylic acid derivative / Quinolizidine / Indole / Quinuclidone / Pyrrole-3-carboxylic acid or derivatives / Quinuclidine / Piperidinone / Piperidine / Substituted pyrrole / Benzenoid
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Conroy T, Cappelaere P, Fabbro M, Fauser AA, Splinter TA, Spielmann M, Schneider M, Chevallier B, Goupil A, Chauvergne J, et al.: Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. Am J Clin Oncol. 1994 Apr;17(2):97-102. [PubMed:8141114]
  3. Reith MK, Sproles GD, Cheng LK: Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug Metab Dispos. 1995 Aug;23(8):806-12. [PubMed:7493546]
  4. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003 Dec 1;98(11):2473-82. [PubMed:14635083]
  5. Monaca-Charley C, Stojkovic T, Duhamel A, De Seze J, Ferriby D, Vermersch P: Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J Neurol. 2003 Oct;250(10):1190-4. [PubMed:14586600]
  6. Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW, Slone AL: Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol. 1992 Aug 14;219(1):9-13. [PubMed:1397053]
  7. Balfour JA, Goa KL: Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997 Aug;54(2):273-98. [PubMed:9257083]
  8. Hui YF, Ignoffo RJ: Dolasetron. A new 5-hydroxytryptamine3 receptor antagonist. Cancer Pract. 1997 Sep-Oct;5(5):324-8. [PubMed:9341357]
  9. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. [PubMed:9506240]
  10. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Sanwald P, David M, Dow J: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9. [PubMed:8723743]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8. Epub 2005 Sep 26. [PubMed:16192915]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Sanwald P, David M, Dow J: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9. [PubMed:8723743]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:42